These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25379431)

  • 41. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
    ; Bangs ME; Emslie GJ; Spencer TJ; Ramsey JL; Carlson C; Bartky EJ; Busner J; Duesenberg DA; Harshawat P; Kaplan SL; Quintana H; Allen AJ; Sumner CR
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):407-20. PubMed ID: 17822337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduced Prefrontal Cortex Activation in Children with Attention-Deficit/Hyperactivity Disorder during Go/No-Go Task: A Functional Near-Infrared Spectroscopy Study.
    Miao S; Han J; Gu Y; Wang X; Song W; Li D; Liu Z; Yang J; Li X
    Front Neurosci; 2017; 11():367. PubMed ID: 28701914
    [No Abstract]   [Full Text] [Related]  

  • 44. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder.
    Spencer T; Biederman J; Heiligenstein J; Wilens T; Faries D; Prince J; Faraone SV; Rea J; Witcher J; Zervas S
    J Child Adolesc Psychopharmacol; 2001; 11(3):251-65. PubMed ID: 11642475
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Newcorn JH; Spencer TJ; Biederman J; Milton DR; Michelson D
    J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):240-8. PubMed ID: 15725968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder.
    Faraone SV; Biederman J; Spencer T; Michelson D; Adler L; Reimherr F; Seidman L
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):664-70. PubMed ID: 16190797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atomoxetine Treatment Strengthens an Anti-Correlated Relationship between Functional Brain Networks in Medication-Naïve Adults with Attention-Deficit Hyperactivity Disorder: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
    Lin HY; Gau SS
    Int J Neuropsychopharmacol; 2015 Sep; 19(3):pyv094. PubMed ID: 26377368
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
    Fuentes J; Danckaerts M; Cardo E; Puvanendran K; Berquin P; De Bruyckere K; Montoya A; Quail D; Escobar R
    J Clin Psychopharmacol; 2013 Dec; 33(6):766-74. PubMed ID: 23963057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fast vs. slow switching from stimulants to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder.
    Cardo E; Porsdal V; Quail D; Fuentes J; Steer C; Montoya A; Anand E; Escobar R
    J Child Adolesc Psychopharmacol; 2013 May; 23(4):252-61. PubMed ID: 23683140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder.
    Waxmonsky JG; Waschbusch DA; Akinnusi O; Pelham WE
    J Child Adolesc Psychopharmacol; 2011 Feb; 21(1):21-32. PubMed ID: 21288121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.
    Troost PW; Steenhuis MP; Tuynman-Qua HG; Kalverdijk LJ; Buitelaar JK; Minderaa RB; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):611-9. PubMed ID: 17069549
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
    Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
    Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuropsychological outcomes across the day in children with attention-deficit/hyperactivity disorder treated with atomoxetine: results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tracking device.
    Wehmeier PM; Schacht A; Wolff C; Otto WR; Dittmann RW; Banaschewski T
    J Child Adolesc Psychopharmacol; 2011 Oct; 21(5):433-44. PubMed ID: 22040189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data.
    Van Brunt DL; Johnston JA; Ye W; Pohl GM; O'Hara NN
    J Manag Care Pharm; 2006 Apr; 12(3):230-8. PubMed ID: 16623607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuroimaging-Aided Prediction of the Effect of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder: A Randomized Controlled Trial.
    Ishii-Takahashi A; Takizawa R; Nishimura Y; Kawakubo Y; Hamada K; Okuhata S; Kawasaki S; Kuwabara H; Shimada T; Todokoro A; Igarashi T; Watanabe K; Yamasue H; Kato N; Kasai K; Kano Y
    Neuropsychopharmacology; 2015 Nov; 40(12):2676-85. PubMed ID: 25936640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
    Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial.
    Trzepacz PT; Spencer TJ; Zhang S; Bangs ME; Witte MM; Desaiah D
    Curr Med Res Opin; 2011; 27 Suppl 2():45-52. PubMed ID: 21973230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.